BioCentury | Feb 1, 2021

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

Horizon’s $3 billion-plus buyout of Viela caps the biotech’s three-year journey as an independent company spun out from AstraZeneca’s MedImmune unit, with an IPO and a drug approval along the path to value creation. It...
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

A deal with antisense heavyweight Ionis attracted the investor firepower fueling Aro’s transition from platform development to product advancement. Aro Biotherapeutics Co. raised an $88 million series A round Tuesday led by Northpond Ventures and...
BioCentury | Oct 1, 2020
Distillery Therapeutics

Calcium channel-targeting peptide to prevent hypertrophic cardiomyopathy

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy A peptide targeting the cardiac calcium channel L-type α-interaction domain, a cytoplasmic portion the channel’s α1C subunit, could prevent hypertrophic cardiomyopathy. In a mouse model of the disease caused by a...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Jan 9, 2020
Company News

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 9, 2019
Company News

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder. Viela Bio Inc. (NASDAQ:VIE) will...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
BioCentury | Jun 17, 2019
Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
BioCentury | May 30, 2019
Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
Items per page:
1 - 10 of 95